Phase I Study of LB-100 With Docetaxel in Solid Tumors

NCT01837667 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumors
Neoplasms
Cancer

Interventions

DRUG: LB-100 for Injection
DRUG: Docetaxel

Sponsor

Lixte Biotechnology Holdings, Inc.